Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis

The optimal treatment for potential AmpC-producing Enterobacteriaceae, including Serratia, Providencia, Citrobacter, Enterobacter, and Morganella species, remains unknown. An updated systematic review and meta-analysis of studies comparing beta-lactam/beta-lactamase inhibitors with carbapenems in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Matthew P, Lee, Robyn S, Cheng, Alexandre P, De L’étoile-Morel, Samuel, Demir, Koray, Yansouni, Cedric P, Harris, Patrick, McDonald, Emily G, Lee, Todd C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656656/
https://www.ncbi.nlm.nih.gov/pubmed/31363762
http://dx.doi.org/10.1093/ofid/ofz248
Descripción
Sumario:The optimal treatment for potential AmpC-producing Enterobacteriaceae, including Serratia, Providencia, Citrobacter, Enterobacter, and Morganella species, remains unknown. An updated systematic review and meta-analysis of studies comparing beta-lactam/beta-lactamase inhibitors with carbapenems in the treatment of bloodstream infections with these pathogens found no significant difference in 30-day mortality (OR, 1.13; 95% CI, 0.58 – 2.20).

Ejemplares similares